Brief: Zai Lab Announces First Patient Treated In Mainland China For Study Of Bemarituzumab
July 14 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB ANNOUNCES FIRST PATIENT TREATED IN MAINLAND CHINA
FOR
THE GLOBAL PHASE 3 FORTITUDE-101 STUDY OF BEMARITUZUMAB IN
FIRST-LINE GASTRIC CANCER
* ZAI LAB LTD - IN EARLY 2024, ZAI LAB WILL JOIN
AMGEN-SPONSORED
GLOBAL PHASE 3 FORTITUDE-102 STUDY IN FIRST-LINE GASTRIC CANCER
Source text for Eikon: ID:nGNXbhW1YH
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows